{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-274258","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2026-06-17T20:36:46+00:00","discovered_at":"2026-06-17T20:38:00.490061+00:00","generated_at":"2026-06-17T20:38:46.398940+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corcept resubmits NDA for relacorilant to FDA for Cushing's syndrome; six-month review expected","bullets":["Resubmission based on pivotal GRACE trial and Phase III GRADIENT trial data.","Includes additional analyses requested by FDA; expects six-month review cycle.","Relacorilant shows durable symptom improvement without serious adverse events like hypokalemia or pregnancy termination.","CEO states company looks forward to working with FDA toward approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-274258","json":"https://secwatch.observer/filing/0001193125-26-274258.json","markdown":"https://secwatch.observer/filing/0001193125-26-274258.md","text":"https://secwatch.observer/filing/0001193125-26-274258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/0001193125-26-274258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/d159941d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:38:46.398940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}